Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders

Z. W. Zhu, H. Friess, L. Wang, M. Abou-Shady, A. Zimmermann, A. D. Lander, Murray Korc, J. Kleeff, M. W. Büchler

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

Background/aims - Hepatocellular carcinoma (HCC) is a common malignant tumour worldwide, and its differential diagnosis from benign lesions of the liver is often difficult yet of great clinical importance. In the present study, we analysed whether glypican-3 is useful in differentiating between benign and malignant liver diseases and whether it influences the growth behaviour of HCC. Methods - Northern blot analysis and in situ hybridisation. Results - Northern blot analysis indicated that expression of glypican-3 mRNA was either low or absent in normal liver, in focal nodular hyperplasia (FNH), and in liver cirrhosis. In contrast, expression of glypican-3 mRNA was markedly increased in 20 of 30 and moderately increased in five of 30 HCC samples. The average increase in glypican-3 mRNA expression in HCC was significant compared with expression in normal liver (21.7-fold increase, p

Original languageEnglish (US)
Pages (from-to)558-564
Number of pages7
JournalGut
Volume48
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Glypicans
Hepatocellular Carcinoma
Liver
Northern Blotting
Messenger RNA
Focal Nodular Hyperplasia
Liver Cirrhosis
In Situ Hybridization
Liver Diseases
Differential Diagnosis
Growth
Neoplasms

Keywords

  • Focal nodular hyperplasia
  • Glypican-3
  • Hepatocellular cancer
  • Liver cirrhosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Zhu, Z. W., Friess, H., Wang, L., Abou-Shady, M., Zimmermann, A., Lander, A. D., ... Büchler, M. W. (2001). Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 48(4), 558-564. https://doi.org/10.1136/gut.48.4.558

Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. / Zhu, Z. W.; Friess, H.; Wang, L.; Abou-Shady, M.; Zimmermann, A.; Lander, A. D.; Korc, Murray; Kleeff, J.; Büchler, M. W.

In: Gut, Vol. 48, No. 4, 2001, p. 558-564.

Research output: Contribution to journalArticle

Zhu, ZW, Friess, H, Wang, L, Abou-Shady, M, Zimmermann, A, Lander, AD, Korc, M, Kleeff, J & Büchler, MW 2001, 'Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders', Gut, vol. 48, no. 4, pp. 558-564. https://doi.org/10.1136/gut.48.4.558
Zhu, Z. W. ; Friess, H. ; Wang, L. ; Abou-Shady, M. ; Zimmermann, A. ; Lander, A. D. ; Korc, Murray ; Kleeff, J. ; Büchler, M. W. / Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. In: Gut. 2001 ; Vol. 48, No. 4. pp. 558-564.
@article{e711c75e4f0d4231b838b5485ecafde1,
title = "Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders",
abstract = "Background/aims - Hepatocellular carcinoma (HCC) is a common malignant tumour worldwide, and its differential diagnosis from benign lesions of the liver is often difficult yet of great clinical importance. In the present study, we analysed whether glypican-3 is useful in differentiating between benign and malignant liver diseases and whether it influences the growth behaviour of HCC. Methods - Northern blot analysis and in situ hybridisation. Results - Northern blot analysis indicated that expression of glypican-3 mRNA was either low or absent in normal liver, in focal nodular hyperplasia (FNH), and in liver cirrhosis. In contrast, expression of glypican-3 mRNA was markedly increased in 20 of 30 and moderately increased in five of 30 HCC samples. The average increase in glypican-3 mRNA expression in HCC was significant compared with expression in normal liver (21.7-fold increase, p",
keywords = "Focal nodular hyperplasia, Glypican-3, Hepatocellular cancer, Liver cirrhosis",
author = "Zhu, {Z. W.} and H. Friess and L. Wang and M. Abou-Shady and A. Zimmermann and Lander, {A. D.} and Murray Korc and J. Kleeff and B{\"u}chler, {M. W.}",
year = "2001",
doi = "10.1136/gut.48.4.558",
language = "English (US)",
volume = "48",
pages = "558--564",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders

AU - Zhu, Z. W.

AU - Friess, H.

AU - Wang, L.

AU - Abou-Shady, M.

AU - Zimmermann, A.

AU - Lander, A. D.

AU - Korc, Murray

AU - Kleeff, J.

AU - Büchler, M. W.

PY - 2001

Y1 - 2001

N2 - Background/aims - Hepatocellular carcinoma (HCC) is a common malignant tumour worldwide, and its differential diagnosis from benign lesions of the liver is often difficult yet of great clinical importance. In the present study, we analysed whether glypican-3 is useful in differentiating between benign and malignant liver diseases and whether it influences the growth behaviour of HCC. Methods - Northern blot analysis and in situ hybridisation. Results - Northern blot analysis indicated that expression of glypican-3 mRNA was either low or absent in normal liver, in focal nodular hyperplasia (FNH), and in liver cirrhosis. In contrast, expression of glypican-3 mRNA was markedly increased in 20 of 30 and moderately increased in five of 30 HCC samples. The average increase in glypican-3 mRNA expression in HCC was significant compared with expression in normal liver (21.7-fold increase, p

AB - Background/aims - Hepatocellular carcinoma (HCC) is a common malignant tumour worldwide, and its differential diagnosis from benign lesions of the liver is often difficult yet of great clinical importance. In the present study, we analysed whether glypican-3 is useful in differentiating between benign and malignant liver diseases and whether it influences the growth behaviour of HCC. Methods - Northern blot analysis and in situ hybridisation. Results - Northern blot analysis indicated that expression of glypican-3 mRNA was either low or absent in normal liver, in focal nodular hyperplasia (FNH), and in liver cirrhosis. In contrast, expression of glypican-3 mRNA was markedly increased in 20 of 30 and moderately increased in five of 30 HCC samples. The average increase in glypican-3 mRNA expression in HCC was significant compared with expression in normal liver (21.7-fold increase, p

KW - Focal nodular hyperplasia

KW - Glypican-3

KW - Hepatocellular cancer

KW - Liver cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=0035086268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035086268&partnerID=8YFLogxK

U2 - 10.1136/gut.48.4.558

DO - 10.1136/gut.48.4.558

M3 - Article

VL - 48

SP - 558

EP - 564

JO - Gut

JF - Gut

SN - 0017-5749

IS - 4

ER -